168 related articles for article (PubMed ID: 28115200)
41. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
42. Expression of androgen receptor splice variants in clinical breast cancers.
Hickey TE; Irvine CM; Dvinge H; Tarulli GA; Hanson AR; Ryan NK; Pickering MA; Birrell SN; Hu DG; Mackenzie PI; Russell R; Caldas C; Raj GV; Dehm SM; Plymate SR; Bradley RK; Tilley WD; Selth LA
Oncotarget; 2015 Dec; 6(42):44728-44. PubMed ID: 26554309
[TBL] [Abstract][Full Text] [Related]
43. Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.
Soekmadji C; Rockstroh A; Ramm GA; Nelson CC; Russell PJ
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 29105980
[TBL] [Abstract][Full Text] [Related]
44. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
Asangani IA; Wilder-Romans K; Dommeti VL; Krishnamurthy PM; Apel IJ; Escara-Wilke J; Plymate SR; Navone NM; Wang S; Feng FY; Chinnaiyan AM
Mol Cancer Res; 2016 Apr; 14(4):324-31. PubMed ID: 26792867
[TBL] [Abstract][Full Text] [Related]
45. Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.
Chow VA; Martin PS; Smith SD; Till BG; Graf SA; Edlefsen KL; Hannan LM; Mostaghel EA; Gopal AK
Br J Haematol; 2020 Sep; 190(6):e332-e335. PubMed ID: 32567674
[No Abstract] [Full Text] [Related]
46. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
[TBL] [Abstract][Full Text] [Related]
47. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
[TBL] [Abstract][Full Text] [Related]
48. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling.
Lu S; Dong Z
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982774
[TBL] [Abstract][Full Text] [Related]
49. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
Xia X; Huang C; Liao Y; Liu Y; He J; Guo Z; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 May; 38(1):220. PubMed ID: 31126320
[TBL] [Abstract][Full Text] [Related]
51. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
[TBL] [Abstract][Full Text] [Related]
52. TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
Feng T; Zhao R; Sun F; Lu Q; Wang X; Hu J; Wang S; Gao L; Zhou Q; Xiong X; Dong X; Wang L; Han B
Oncogene; 2020 Jan; 39(2):356-367. PubMed ID: 31477836
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
54. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.
Wang J; Zou JX; Xue X; Cai D; Zhang Y; Duan Z; Xiang Q; Yang JC; Louie MC; Borowsky AD; Gao AC; Evans CP; Lam KS; Xu J; Kung HJ; Evans RM; Xu Y; Chen HW
Nat Med; 2016 May; 22(5):488-96. PubMed ID: 27019329
[TBL] [Abstract][Full Text] [Related]
55. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
56. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
57. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.
Alimirah F; Chen J; Basrawala Z; Xin H; Choubey D
FEBS Lett; 2006 Apr; 580(9):2294-300. PubMed ID: 16580667
[TBL] [Abstract][Full Text] [Related]
58. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
[TBL] [Abstract][Full Text] [Related]
59. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
60. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
